Prothena(PRTA) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, Prothena reported a net cash used in operating and investing activities of $163.7 million, which was favorable compared to the guidance range of $170 million to $178 million [35] - The net loss for 2025 was $244.1 million, aligning with the guidance range of $240 million to $248 million [35] - As of December 31, 2025, Prothena had $308.4 million in cash, cash equivalents, and restricted cash, exceeding the guidance of $298 million [36] Business Line Data and Key Metrics Changes - Prothena's clinical pipeline saw significant advancements, with two partnered programs, prasinezumab and coramitug, moving into phase 3 clinical trials [5] - The phase 3 PARAISO trial for prasinezumab will evaluate 900 participants with early Parkinson's disease, while the CLEOPATTRA trial for coramitug will enroll approximately 1,280 patients with ATTR-CM [5][17] - The company anticipates potential milestone payments of up to $105 million in 2026 from these partnered programs [9][38] Market Data and Key Metrics Changes - The global market for Parkinson's disease treatment is significant, with over 10 million patients and no approved disease-modifying therapies currently available [13] - The ATTR-CM market represents a multi-billion dollar opportunity, with coramitug expected to capture substantial future milestone payments [18] Company Strategy and Development Direction - Prothena aims to capture value from its clinical partnerships and has a strategic priority to implement a share redemption program in 2026 [9][39] - The company is focused on advancing its preclinical portfolio and exploring research collaborations, particularly around its CYTOPE technology [9][39] - Prothena's strategic priorities are supported by a robust cash position, allowing for prudent capital utilization [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's execution and resilience in 2025, setting the stage for future growth [39] - The company is optimistic about the potential for significant medical advances in areas with high unmet needs, particularly in neurodegenerative diseases [42] - Management highlighted the importance of upcoming milestones and the potential for substantial clinical milestone payments in 2026 [46] Other Important Information - Prothena's collaborations with Bristol Myers Squibb progressed, with the phase 2 TargetTau-1 trial for BMS-986446 fully enrolled and expected to complete in the first half of 2027 [6] - The company introduced its CYTOPE technology, which aims to enable precise targeting of intracellular disease pathways [27] Q&A Session Summary Question: Key milestones for partnered program trials for PARAISO and CLEOPATTRA - Management outlined that significant activities are expected in 2026 and 2027, including updates on CYTOPE technology and data from the tau program with Bristol Myers Squibb [41][42] Question: Keeping the amyloid beta story alive versus competitors - Management discussed the advantages of the PRX012 transferrin-based approach, emphasizing its potential for robust amyloid removal and improved safety profile [50][52] Question: Data sharing from the phase one study of PRX019 - Management confirmed that data from the PRX019 study will be shared with Bristol Myers Squibb, who holds global rights to the program [61][66] Question: Data necessary for CYTOPE platform partnerships - Management highlighted the importance of demonstrating robust CNS activity and specificity in targeting TDP-43 aggregates to attract partnerships [69][73]